Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The company is headquartered in Mississauga, Ontario and currently employs 14 full-time employees. The company went IPO on 2009-09-03. The firm is focused on the commercialization and development of prescription products, with a primary focus in the field of men's health. Its product, Natesto, a testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Its product pipeline includes Avanafil, Lidbree, and Tefina. Avanafil is a chemical entity, PDE5 inhibitor for the treatment of erectile dysfunction in men. Lidbree, is a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue. The company also has product rights to Tefina, a clinical stage product aimed at addressing an unmet need for women with female sexual dysfunction. Its primary market is the United States, where it commercializes its product with its contract commercial provider, Syneos Health (Syneos). The company commercializes its products via its own salesforce in the United States and Canada.